Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Communications Biology|October 23, 2020
Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSAMaria Celeste Varela, Melanie Roch, Agustina Taglialegna, et al.
Breast Cancer Research : BCR|May 22, 2020
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerLori J Goldstein, Raymond P Perez, Denise Yardley, et al.
Antimicrobial Agents and Chemotherapy|November 1, 2016
Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureusAdriana Renzoni, William L Kelley, Roberto R Rosato, et al.
Breast Cancer Research : BCR|January 12, 2020
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancerLori J Goldstein, Raymond P Perez, Denise Yardley, et al.
European Journal of Neurology|July 4, 2020
Box and block test, hand grip strength and nine-hole peg test: correlations between three upper limb objective measures in multiple sclerosisC Solaro, R Di Giovanni, E Grange, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2018
Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast CancerDaniel Dávila-González, Dong Soon Choi, Roberto R Rosato, et al.
Leukemia|August 26, 2006
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trialM Ladetto, S Vallet, F Benedetti, et al.
Leukemia|February 16, 2007
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsI Ricca, A Rocci, D Drandi, et al.
Breast Cancer Research : BCR|September 4, 2019
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)Tejal A Patel, Joe E Ensor, Sarah L Creamer, et al.
Nature Communications|December 18, 2021
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosisFan Yao, Yalan Deng, Yang Zhao, et al.
Pageof 10